Langerhans cell function

Langerhans cells (LCs) are specialized, dendritic antigen-presenting cells residing in the epidermis that function as the primary immune sentinels of the skin [1, 15]. Langerhans cell function refers to the biological processes of these cells, including antigen capture via C-type lectin receptors like Langerin (CD207), subsequent maturation, and migration to skin-draining lymph nodes to initiate adaptive immunity or maintain peripheral tolerance [12, 16]. While not a single molecular entity, LC function is critically regulated by the MAPK/ERK signaling pathway, which is frequently dysregulated in Langerhans cell histiocytosis (LCH) [2, 14]. LCH is characterized by the pathological accumulation of LCs driven by somatic mutations, most commonly the BRAF V600E mutation, leading to inflammatory lesions and organ dysfunction [3, 8]. Targeted therapies such as BRAF inhibitors (e.g., vemurafenib) and MEK inhibitors (e.g., cobimetinib) have been developed to modulate LC function by inhibiting the overactive signaling pathways responsible for their uncontrolled proliferation [2, 6]. Additionally, targeting LC-specific receptors like Langerin is a major focus in the development of epicutaneous vaccines and immunotherapies for cancer and infectious diseases [10, 11].

Other names

LC functionLangerhans cell activitySkin dendritic cell functionEpidermal dendritic cell function

Targeted inhibition of the MAPK signaling pathway (e.g., BRAF and MEK inhibition) to suppress pathological proliferation; use of systemic corticosteroids and cytotoxic chemotherapy (e.g., vinblastine) for cell depletion; and receptor-mediated antigen delivery targeting C-type lectins (e.g., Langerin) to modulate immune responses.